How many 8-K filings has Vaxcyte, Inc. filed?

Vaxcyte, Inc. (PCVX) has 11 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Vaxcyte, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Vaxcyte, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Vaxcyte, Inc. (PCVX) — 8-K Filings

All 8-K filings from Vaxcyte, Inc.. Browse 11 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (11)

Vaxcyte, Inc. Files 8-K: Officer/Director Changes & Financials — Dec 19, 2025 Risk: low
Vaxcyte, Inc. filed an 8-K on December 19, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of cert
Vaxcyte, Inc. Enters Material Definitive Agreement — Sep 30, 2025 Risk: medium
On September 24, 2025, Vaxcyte, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement or any asso
Vaxcyte, Inc. Files 8-K on Shareholder Vote Matters — Jun 17, 2025 Risk: low
Vaxcyte, Inc. filed an 8-K on June 17, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details routine corpor
Vaxcyte Announces Board Changes and Executive Compensation Updates — May 1, 2025 Risk: low
On May 1, 2025, Vaxcyte, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the
8-K Filing — Mar 31, 2025
Vaxcyte Amends Credit Agreement with OrbiMed — Nov 21, 2024 Risk: medium
On November 15, 2024, Vaxcyte, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to its Second Amended and Restated Credit Agre
Vaxcyte Files 8-K: Other Events & Exhibits — Sep 6, 2024 Risk: low
Vaxcyte, Inc. filed an 8-K on September 6, 2024, reporting an "Other Event" and "Financial Statements and Exhibits" as of September 4, 2024. The filing does not
Vaxcyte, Inc. Files 8-K Report — Sep 3, 2024 Risk: low
On September 3, 2024, Vaxcyte, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclo
Vaxcyte Appoints New CMO, CDO; Adds Director — Jul 2, 2024 Risk: low
Vaxcyte, Inc. announced on June 27, 2024, the appointment of Dr. Sarah E. Bloch as Chief Medical Officer and Dr. David L. Gordon as Chief Development Officer. T
Vaxcyte, Inc. Reports on Security Holder Meeting — Jun 10, 2024 Risk: low
Vaxcyte, Inc. filed an 8-K on June 10, 2024, reporting on a meeting of security holders held on June 6, 2024. The filing indicates that the company's security h
Vaxcyte Files Routine 8-K, Confirms Registration Details — Jan 31, 2024
Vaxcyte, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024. This filing is a routine update, primarily confirming the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX